Given the importance of amyloid plaque deposition and NFT formation in the early stages of AD, drug therapies that can reduce the amyloid peptide load, inhibit Tau phosphorylation, or protect vulnerable neurons against downstream pathogenic processes may prevent the associated cognitive dysfunction. This evidence concerns the gene MAPT and Alzheimer disease.